B-type natriuretic peptide for the treatment of congestive heart failure

Current Opinion in Pharmacology

Volumn 2, Issue 2, 2002, Pages 142-147

  Schreiner, George F ^a   Protter, Andrew A ^a  

^a SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; GLYCERYL TRINITRATE; NESIRITIDE; RECOMBINANT HORMONE;

ARTICLE; BLOOD VOLUME; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DIURESIS; HEART AFTERLOAD; HEART BLOOD VESSEL; HEART OUTPUT; HEART PRELOAD; HEART VENTRICLE; HORMONE RELEASE; HUMAN; KIDNEY BLOOD VESSEL; LUNG BLOOD VESSEL; LUNG CAPILLARY PRESSURE; NATRIURESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; SODIUM EXCRETION; URINARY EXCRETION;

EID: 0036535376     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00142-X     Document Type: Review

References (40)

1. Isolation and identification of human brain natriuretic peptides in cardiac atrium
2. The pathophysiology of advanced heart failure
3. Pathophysiology and clinical spectrum of acute congestive heart failure
4. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
5. Discovery of a natriuretic peptide family and their clinical application
6. Mechanical load-induced alterations in B-type natriuretic peptide gene expression
7. Stabilization of the B-type natriuretic peptide mRNA in cardiac myocytes by alpha-adrenergic receptor activation: Potential roles for protein kinase C and mitogen-activated protein kinase
8. Src and Rac mediate endothelin-1 and lysophosphatidic acid stimulation of the human brain natriuretic peptide promoter
9. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes
10. Brain natriuretic peptide as a cardiac hormone in cardiovascular diseases
11. Receptors of natriuretic peptides
12. Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide
13. Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity
14. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment
15. Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides
16. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle
17. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue
18. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells
19. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs
20. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney
21. Atrial and brain natriuretic peptide in adrenal steroidogenesis
22. Sympathoinhibitory effects of atrial natriuretic factor in normal humans
23. Nonuniform enhancement of baroreflex sensitivity by atrial natriuretic peptide in conscious rats and dogs
24. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney
25. Effect of atriopeptin II on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus
26. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner-medullary collecting duct cells
27. Brain natriuretic peptide: Effect of left ventricular filling patterns in healthy subjects
28. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts
29. C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells
30. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart
31. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure
32. Hormones and hemodynamics in heart failure
33. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure
34. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial
35. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
36. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
37. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial
38. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy
39. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
40. Sustained symptom improvement with nesiritide (B-type natriuretic peptide) compared to IV nitroglycerin in patients with acute decompensated heart failure